筛查依从性对长期全因死亡率和结直肠癌死亡率降低效果的影响
该研究汇总丹麦结直肠癌筛查试验(n=61,933)和明尼苏达结肠癌对照试验(n=46,551)的个体数据,随访30年,比较每两年一次粪隐血试验(FOBT)筛查组与常规照护组。依从者中,筛查使结直肠癌死亡率降低16%(RR 0.84),全因死亡率降低2%(RR 0.98);男性结直肠癌死亡率降低幅度大于女性,女性获益约滞后10年。
要点
- 依从者中每两年FOBT筛查使结直肠癌死亡率降低16%(RR 0.84;95%CI 0.74-0.96)。
- 依从者中筛查使全因死亡率降低2%(RR 0.98;95%CI 0.97-0.99)。
- 男性结直肠癌死亡率降低幅度大于女性,女性获益约滞后10年。
核心结论
- 依从者中每两年FOBT筛查的长期结直肠癌死亡率获益持续存在,全因死亡率降低有统计学意义。
- 结直肠癌死亡率降低幅度男性大于女性,女性获益约滞后男性10年。
研究设计与样本
- 更新丹麦结直肠癌筛查试验(n=61,933)至30年随访的结直肠癌与全因死亡率数据,并与明尼苏达结肠癌对照试验(n=46,551)的个体30年随访数据汇总。
- 采用Kaplan-Meier法估计相对危险度和危险差,校正研究间年龄、性别和依从性差异,比较50-80岁人群每两年筛查组与常规照护组。
主要发现
- 30年随访期间,每两年筛查组(n=46,553)和对照组(n=46,358)的全因死亡分别为33,478例(71.9%)和33,479例(72.2%),结直肠癌死亡分别为1023例(2.2%)和1146例(2.5%)。
- 依从者中,每两年FOBT筛查使结直肠癌死亡率降低16%(RR 0.84;95%CI 0.74-0.96),全因死亡率降低2%(RR 0.98;95%CI 0.97-0.99)。
- 依从者中,男性结直肠癌死亡率降低幅度(RR 0.75;95%CI 0.62-0.90)大于女性(RR 0.91;95%CI 0.75-1.09)。
- 依从者中结直肠癌死亡率降低幅度最大的是60-69岁男性(RR 0.59;95%CI 0.42-0.81)和70岁及以上女性(RR 0.53;95%CI 0.30-0.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Randomized trials have shown that biennial fecal occult blood test (FOBT) screening reduces mortality from colorectal cancer (CRC), but not overall mortality. Differences in benefit for men vs women, and by age, are unknown. We sought to evaluate long-term reduction in all-cause and CRC-specific mortality in men and women who comply with offered screening, and in different age groups, using individual participant data from 2 large randomized trials of biennial FOBT screening, compared with an intention to treat analysis. METHODS: We updated the CRC and all-cause mortality from the Danish CRC screening trial (n = 61,933) through 30 years of follow up and pooled individual participant data with individual 30-year follow-up data from the Minnesota Colon Cancer Control trial (n = 46,551). We compared the biennial screening groups to usual care (controls) in individuals 50-80 years old using Kaplan Meier estimates of relative risks and risk differences, adjusted for study differences in age, sex, and compliance. RESULTS: Through 30 years of follow up, there were 33,478 (71.9%) and 33,479 (72.2%) total deaths and 1023 (2.2%) and 1146 (2.5%) CRC deaths in the biennial screening (n = 46,553) and control groups (n = 46,358), respectively. Among compliers, biennial FOBT screening significantly reduced CRC mortality by 16% (relative risk [RR], 0.84; 95% CI, 0.74-0.96) and all-cause mortality by 2% (RR, 0.98; 95% CI, 0.97-0.99). Among compliers, the reduction in CRC mortality was larger for men (RR, 0.75; 95% CI, 0.62-0.90) than women (RR, 0.91; 95% CI, 0.75-1.09). The largest reduction in CRC mortality was in compliant men 60-69 years old (RR, 0.59; 95% CI, 0.42-0.81) and women 70 years and older (RR, 0.53; 95% CI, 0.30-0.94). CONCLUSIONS: Long-term CRC mortality outcomes of screening among compliers using biennial FOBT are sustained, with a statistically significant reduction in all-cause mortality. The reduction in CRC mortality is greater in men than women-the benefit in women lags that of men by about 10 years.
引用
- Shaukat A, Kaalby L, Baatrup G, et al. Effects of Screening Compliance on Long-term Reductions in All-Cause and Colorectal Cancer Mortality. Clin Gastroenterol Hepatol. 2020. PMID: 32634624. doi:10.1016/j.cgh.2020.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。